
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
– VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement – – Zimislecel (VX-880) pivotal trial on track to complete enrollment and …